An observational study in Platelet Activation, Thromboinflammation and Sickle Cell Disease, sponsored by University Hospital, Toulouse. Active, not recruiting at 1 site in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by University Hospital, Toulouse · Observational
Sickle cell disease (SCD) is an autosomal recessive genetic disorder linked to a single mutation on beta-globin chains. This leads to red blood cell deformation and chronic hemolysis which can result in vaso-occlusive events, anemia and vasculopathy. Pathophysiology is incompletely understood, and beyond red blood cell's abnormalities this involves hemostasis and innate immunity. The aim of our study is to describe the mechanisms of thrombo-inflammation during the vaso-occlusive crisis (VOC) in adults with sickle cell disease.
Pathophysiology of sickle cell disease is incompletely understood. The typical change of red blood cells into sickle cells lead to post-capillary stream abnormalities. This phenomenon is responsible of ischemia-reperfusion injuries. Chronic hemolysis is the second part of the pathophysiology. The consequences are vasoconstriction, endothelial lesions, chronic inflammation, hemostasis and platelets activation. Thrombo-inflammation concept was proposed by Tanguay to describe the interactions between hemostasis, platelets and innate immune cells (neutrophils polynuclear) during thrombotic process. Since this time, this concept was largely described in many clinical situations such as septicemia, COVID-19, coronaropathy, auto-immune diseases and sickle cell disease.
In this project, we will study platelets activation and thrombo-inflammation markers in the beginning of a vaso-occlusive crisis, during the crisis and two months after the crisis. Blood samples will be collected during a routine care sample.
Biological markers studied will be:
1,103 studies on the registry are indexed under Anemia, Sickle Cell; 235 are open to participants now.
This study's planned enrollment of 25 is below the median of 100 across 287 observational studies indexed under Anemia, Sickle Cell.
Browse Anemia, Sickle Cell studies →University Hospital, Toulouse is the lead sponsor of 794 studies on the registry; 214 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with sickle cell disease diagnosis
Exclusion Criteria:
the blood sample will be taken during a planned blood sampling
To evaluate mechanisms of platelet activation in the thrombo-inflammation process during a vaso-occlusive crisis.
by flow cytometry analysis
Time frame: First 48h of hospitalization
To evaluate mechanisms of platelet activation in the thrombo-inflammation process during a vaso-occlusive crisis.
by flow cytometry analysis
Time frame: Day 13 (+/- 2 days)
To evaluate mechanisms of platelet activation in the thrombo-inflammation process during a vaso-occlusive crisis.
by flow cytometry analysis
Time frame: At day 60 (+/- 2 days)
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Thromboinflammation
University Hospital, Toulouse